| Literature DB >> 32423515 |
Marie A de Perio1, Chad H Dowell2, Lisa J Delaney2, Lewis J Radonovich3, David T Kuhar4, Neil Gupta5, Anita Patel6, Satish K Pillai7, Maryann D'Alessandro3.
Abstract
N95 respirators are personal protective equipment most often used to control exposures to infections transmitted via the airborne route. Supplies of N95 respirators can become depleted during pandemics or when otherwise in high demand. In this paper, we offer strategies for optimizing supplies of N95 respirators in health care settings while maximizing the level of protection offered to health care personnel when there is limited supply in the United States during the 2019 coronavirus disease pandemic. The strategies are intended for use by professionals who manage respiratory protection programs, occupational health services, and infection prevention programs in health care facilities to protect health care personnel from job-related risks of exposure to infectious respiratory illnesses. Consultation with federal, state, and local public health officials is also important. We use the framework of surge capacity and the occupational health and safety hierarchy of controls approach to discuss specific engineering control, administrative control, and personal protective equipment measures that may help in optimizing N95 respirator supplies.Entities:
Keywords: emergency preparedness; infection control; occupational health; pandemics; surge capacity
Year: 2020 PMID: 32423515 PMCID: PMC7303467 DOI: 10.1017/dmp.2020.160
Source DB: PubMed Journal: Disaster Med Public Health Prep ISSN: 1935-7893 Impact factor: 1.385
Respirators Approved Under Standards Used in Other Countries That Are Similar to NIOSH-Approved N95 Filtering Facepiece Respirators
| Country | Performance Standard | Acceptable Product Classification | May Be Used in Lieu of NIOSH-Certified Products Classified as: |
|---|---|---|---|
| Australia | AS/NZS 1716:2012 | P2 | N95 |
| P3 | N99 or lower | ||
| Brazil | ABNT/NBR 13698:2011 | PFF2 | N95 |
| PFF3 | N99 or lower | ||
| People’s Republic of China | GB 2626-2006 | KN/KP95 | N95 |
| KN/KP100 | N95 | ||
| Europe | EN 149-2001 | P2 | N95 |
| P3 | N99 or lower | ||
| Japan | JMHLW-2000 | DS/DL2 | N95 |
| DS/DL3 | N99 or lower | ||
| Korea | KMOEL-2017-64 | Special 1st | N95 |
| Mexico | NOM-116-2009 | N95 | N95 |
| R95 | R95 or lower | ||
| P95 | P95 or lower | ||
| N99 | N99 or lower | ||
| R99 | R99 or lower | ||
| P99 | P99 or lower | ||
| N100 | N100 or lower | ||
| R100 | R100 or lower | ||
| P100 | P100 or lower |
Respirator-Cartridge Units Approved Under Standards Used in Other Countries That Are Similar to NIOSH-Approved Elastomeric Half-Facepiece Respirators
| Country | Performance Standard | Acceptable Product Classification | May Be Used in Lieu of NIOSH-Certified Products Classified as: |
|---|---|---|---|
| Australia | AS/NZS 1716:2012 | P2 | N95 |
| P3 | N99 or lower | ||
| Brazil | ABNT/NBR 13694:1996; ABNT/NBR 13697:1996 | P2 | N95 |
| P3 | N99 or lower | ||
| People’s Republic of China | GB 2626-2006; | KN/KP95 | N95 |
| GB 2626-2019 | KN/KP100 | N95 | |
| Europe | EN140-1999; | P2 | N95 |
| P3 | N99 or lower | ||
| Japan | JMHLW-2000 | RS/RL2 | N95 |
| RS/RL3 | N99 or lower | ||
| Korea | KMOEL-2014-46 | Special 1st | N95 |
| Mexico | NOM-116-2009 | N95 | N95 |
| R95 | R95 or lower | ||
| P95 | P95 or lower | ||
| N99 | N99 or lower | ||
| R99 | R99 or lower | ||
| P99 | P99 or lower | ||
| N100 | N100 or lower | ||
| R100 | R100 or lower | ||
| P100 | P100 or lower |
Suggested Face Mask or Respirator Use, Based Upon Distance From a Patient With Suspected or Known COVID-19 and Use of Source Control[*]
| HCP Planned Proximity to the Case Patient During Encounter | Face Mask or Respirator Determination | |
|---|---|---|
| Patient Masked for Entire Encounter | Unmasked Patient or Mask Needs to be Removed for Any Period of Time During the Patient Encounter | |
| HCP will remain at greater than 6 feet from symptomatic patient. | If HCP must enter the patient care area: no face mask or respirator. | If HCP must enter the patient care area: no face mask or respirator. |
| HCP will be within 6 feet of symptomatic patient, including providing direct patient care. | Face Mask | Any NIOSH-approved N95 respirator/ elastomeric/PAPR, based on availability or face mask if respirator unavailable. |
| HCP will be present in the room during aerosol-generating procedures performed on symptomatic persons. | Any NIOSH-approved N95 respirator/ elastomeric/PAPR, based on availability. | Any NIOSH-approved N95 respirator/ elastomeric/PAPR, based on availability. |
Based on availability, organizations may require and/or individuals may voluntarily choose to use higher levels of protection. COVID-19 = 2019 novel coronavirus disease; HCP = health care personnel; PAPR = powered air-purifying respirator.